preoperative chemotherapy for all patients with osteogenic sarcoma would seem to offer the following advantages : 1 ) evaluation of the effect of hdmtx with cfr on the primary tumor with escalation of the dose of hdmtx until a clinical response is observed , thus defining the dose of hdmtx effective in that patient , to be continued postoperatively as adjuvant therapy ;
C0029463
osteogenic sarcoma
C0025677
hdmtx